STADA Arzneimittel AG (ETR:SAZ) has been given a €58.00 ($68.24) price objective by analysts at Commerzbank Ag in a research note issued to investors on Wednesday. The firm presently has a “sell” rating on the stock.

Several other equities analysts have also commented on the company. Independent Research GmbH set a €66.25 ($77.94) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Wednesday, August 9th. S&P Global set a €66.25 ($77.94) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Thursday, August 3rd. Kepler Capital Markets set a €66.00 ($77.65) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Tuesday, July 11th. Finally, Warburg Research set a €60.00 ($70.59) target price on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating and two have given a hold rating to the stock. The company presently has a consensus rating of “Sell” and a consensus price target of €65.30 ($76.82).

STADA Arzneimittel AG (ETR SAZ) traded up 4.549% on Wednesday, reaching €75.275. The company had a trading volume of 11,514 shares. The company has a market capitalization of €4.69 billion and a PE ratio of 49.752. STADA Arzneimittel AG has a 52-week low of €41.40 and a 52-week high of €75.28. The company’s 50-day moving average is €65.34 and its 200-day moving average is €61.72.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/21/commerzbank-ag-reiterates-58-00-price-target-for-stada-arzneimittel-ag-saz.html.

About STADA Arzneimittel AG

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.

Analyst Recommendations for STADA Arzneimittel AG (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.